ResearchReducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
ResearchAdvancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
ResearchData-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
ResearchComplete remission of fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib
ResearchToward a More Patient-Centered Drug Development Process in Clinical Trials for Patients With Myelodysplastic Syndromes/Neoplasms (MDS): Practical Considerations From the International Consortium for MDS (icMDS)
ResearchNon-canonical FLT3 Alterations Reveal Novel Germline FLT3 Variants Leading to Somatic Gene Rescue Mutations
ResearchContemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
ResearchTargeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
ResearchAn agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
ResearchValidation of the Molecular International Prognostic Scoring System in Patients With Myelodysplastic Syndromes
ResearchConsensus Proposal for Revised International Working Group 2023 Response Criteria for Higher-Risk Myelodysplastic Syndromes